IGHI IGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use AZITHROMYCIN FOR ORAL SUSPENSION safely and effectively. See full prescribing information for AZITHROMYCIN FOR ORAL SUSPENSION.

AZITHROMYCIN for oral suspension Initial U.S. Approval: 1991

--- INDICATIONS AND USAGE----

Azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria:

- Acute bacterial exacerbations of chronic bronchitis in adults (1.1)
- Acute bacterial sinusitis in adults (1.1)
- Uncomplicated skin and skin structure infections in adults (1.1)
- Urethritis and cervicitis in adults (1.1)
- Genital ulcer disease in men (1.1)
- Acute otitis media in pediatric patients (6 months of age and older) (1.2)
- Community-acquired pneumonia in adults and pediatric patients (6 months of age and older) (1.1, 1.2)
- Pharyngitis/tonsillitis in adults and pediatric patients (2 years of age and older) (1.1, 1.2)

Limitation of Use

Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors. (1.3)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.4)

--DOSAGE AND ADMINISTRATION------

Adult Patients (2.1)

ł	Infection	Recommended Dose/Duration of Therapy
	Community-acquired pneumonia (mild severity) Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated)	500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.
	Acute bacterial exacerbations of chronic bronchitis (mild to moderate)	500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days.
ł	Acute bacterial sinusitis	500 mg once daily for 3 days.
11111	Genital ulcer disease (chancroid) Non-gonococcal urethritis and cervicitis	One single 1 gram dose.
1	Gonococcal urethritis and cervicitis	One single 2 gram dose.

Pediatric Patients (2.2)

Infection	Recommended Dose/Duration of Therapy
Acute otitis media (6 months of age and older)	30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5.

Acute bacterial sinusitis (6 months of age and older)	10 mg/kg once daily for 3 days.
Community-acquired pneumonia (6 months of age and older)	10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5.
Pharyngitis/tonsillitis	12 mg/kg once daily for 5 days.
(2 years of age and older)	

-DOSAGE FORMS AND STRENGTHS-

Azithromycin for oral suspension 200 mg/5 mL (3)

-- CONTRAINDICATIONS--

- Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drua. (4.1)
- Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. (4.2)

--WARNINGS AND PRECAUTIONS-----

- Serious (including fatal) allergic and skin reactions: Discontinue azithromycin if reaction occurs. (5.1)
- Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur. (5.2)
- Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. (5.3)
- · Prolongation of QT interval and cases of torsades de pointes have been reported. This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (5.4)
- Clostridium difficile-Associated Diarrhea: Evaluate patients if diarrhea occurs. (5.5)
- Azithromycin may exacerbate muscle weakness in persons with myasthenia gravis. (5.6)

----ADVERSE REACTIONS-----------

Most common adverse reactions are diarrhea (5 to 14%), nausea (3 to 18%), abdominal pain (3 to 7%), or vomiting (2 to 7%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Taro Pharmaceuticals U.S.A., Inc. at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

--DRUG INTERACTIONS---_____

- Nelfinavir: Close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. (7.1)
- Warfarin: Use with azithromvcin may increase coagulation times: monitor prothrombin time. (7.2)

----USE IN SPECIFIC POPULATIONS-----

- Pediatric use: Safety and effectiveness in the treatment of patients under 6 months of age have not been established. (8.4)
- Geriatric use: Elderly patients may be more susceptible to development of torsades de pointes arrhythmias. (8.5)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Issued: 6/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

1.1 Adult Patients 1.2 Pediatric Patients 1.3 Limitations of Use 1.4 Usage 2 DOSAGE AND ADMINISTRATION 2.1 Adult Patients 2.2 Pediatric Patients **3 DOSAGE FORMS AND STRENGTHS** 4 CONTRAINDICATIONS 4.1 Hypersensitivity 4.2 Hepatic Dysfunction 5 WARNINGS AND PRECAUTIONS 5.1 Hypersensitivity Hepatotoxicity 5.3 Infantile Hypertrophic Pyloric Stenosis (IHPS) 5.4 QT Prolongation 5.5 *Clostridium difficile*-Associated Diarrhea **14 CLINICAL STUDIES** 5.6 Exacerbation of Myasthenia Gravis 5.7 Use in Sexually Transmitted Disease 5.8 Development of Drug-Resistant Bacteria 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 6.3 Laboratory Abnormalities FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Azithromycin is a macrolide antibacterial drug indicated for the • Acute otitis media (>6 months of age) caused by : treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae. Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae. Moraxella catarrhalis, or Streptococcus pneumoniae.

- Community-acquired pneumonia due to Chlamydophila Azithromycin should not be used in patients with pneumonia appropriate for oral therapy.
- Pharvnoitis/tonsillitis caused by Streptococcus
 patients with cystic fibrosis. pyogenes as an alternative to first-line therapy in

 patients with posocomial infections. individuals who cannot use first-line therapy.
- Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae.
- Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria conorrhoeae
- Genital ulcer disease in men due to Haemophilus ducrevi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin **1.4 Usage** in the treatment of chancroid in women has not been established.

7.1 Nelfinavir 7.2 Warfarin 7.3 Potential Drug-Drug Interactions with Macrolides 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 2.2 Pediatric Patients 14.1 Adult Patients 14.2 Pediatric Patients

7 DRUG INTERACTIONS

16 HOW SUPPLIED/STORAGE AND HANDI ING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

1.2 Pediatric Patients

[see Use in Specific Populations (8.4) and Clinical Studies

- Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumonia
- Community-acquired pneumonia (>6 months of age) due to Chlamydophila pneumopiae. Haemophilus influenzae. Mycoplasma pneumoniae. or Streptococcus pneumoniae in patients appropriate for oral therapy.
- Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus progenes as an alternative to first-line therapy in individuals who cannot use first-line therapy

1.3 Limitations of Use

pneumoniae, Haemophilus influenzae, Mycoplasma who are judged to be inappropriate for oral therapy because pneumoniae or Streptococcus pneumoniae in patients of moderate to severe illness or risk factors such as any of the

- natients with known or suspected bacteremia
- patients requiring hospitalization.
- elderly or debilitated patients, o
- patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional

To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial

drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

DOSAGE AND ADMINISTRATION

2.1 Adult Patients

[see Indications and Usage (1,1) and Clinical Pharmacology (12,3)]

Infection*	Recommended Dose/Duration of Therapy	
Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated)	500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5	
Acute bacterial exacerbations of chronic obstructive pulmonary disease	500 mg once daily for 3 days OR 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5	
Acute bacterial sinusitis	500 mg once daily for 3 days	
Genital ulcer disease (chancroid)	One single 1 gram dose	
Non-gonococcal urethritis and cervicitis	One single 1 gram dose	
Gonococcal urethritis and cervicitis	One single 2 gram dose	
*DUE TO THE INDICATED ORGANISMS [see Indic	ations and Usage (1.1)]	

Infection*	Recommended Dose/Duration of Therapy
Acute otitis media	30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5.
Acute bacterial sinusitis	10 mg/kg once daily for 3 days.
Community-acquired pneumonia	10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5.
Pharyngitis/tonsillitis	12 mg/kg once daily for 5 days.
*DUE TO THE INDICATED ORGANISM ¹ see dosing tables below for maximu	

zithromycin for oral suspension can be taken with or without food.

PEDIATRIC DOSAGE GUIDELINES FOR OTITIS MEDIA. ACUTE BACTERIAL SINUSITIS. AND COMMUNITY-ACOUIRED PNEUMONIA (Age 6 months and above, [see Use in Specific Populations (8.4)]) Based on Body Weight

C	OTITIS MEDIA AND COMMUNITY-ACQUIRED PNEUMONIA: (5-Day Regimen)*								
	Dosing Calculated on 10 mg/kg/day Day 1 and 5 mg/kg/day Days 2 to 5.								
Weight	100 mg	J/5 mL	200 mg/5 mL Day 1 Days 2 to 5		Total mL per	Total mg per			
Kg	Day 1	Days 2 to 5			Treatment Course	Treatment Course			
5	2.5 mL; (½ tsp)	1.25 mL; (¼ tsp)			7.5 mL	150 mg			
10	5 mL; (1tsp)	2.5 mL; (½ tsp)			15 mL	300 mg			
20			5 mL; (1 tsp)	2.5 mL; (½ tsp)	15 mL	600 mg			
30			7.5 mL; (1½ tsp)	3.75 mL; (¾ tsp)	22.5 mL	900 mg			
40			10 mL; (2 tsp)	5 mL; (1 tsp)	30 mL	1200 mg			
50 and above			12.5 mL; (2½ tsp)	6.25 mL; (1¼ tsp)	37.5 mL	1500 mg			

has not been established.

OTITIS MEDIA AND ACUTE BACTERIAL SINUSITIS: (3-Day Regimen)*									
	Dosing Calculated on 10 mg/kg/day.								
Weight									
Kg	Days 1 to 3	Days 1 to 3	Treatment Course	Treatment Course					
5	2.5 mL; (½ tsp)		7.5 mL	150 mg					
10	5 mL; (1 tsp)		15 mL	300 mg					
20		5 mL (1 tsp)	15 mL	600 mg					
30		7.5 mL (1½ tsp)	22.5 mL	900 mg					
40		10 mL (2 tsp)	30 mL	1200 mg					
50 and above		12.5 mL (2½ tsp)	37.5 mL	1500 mg					

ectiveness of the 5-day or 1-day regimen in pediatric patients with acute bacterial sinusitis has not been established.

OTITIS MEDIA: (1-Day Regimen)							
Dosing Calculated on 30 mg/kg as a single dose.							
Weight 200 mg/5 mL Total mL per Total mg per							
Kg	1-Day Regimen	Treatment Course	Treatment Course				
5	3.75 mL; (¾ tsp)	3.75 mL	150 mg				
10	7.5 mL; (1½ tsp)	7.5 mL	300 mg				
20	15 mL; (3 tsp)	15 mL	600 mg				
30	22.5 mL; (4½ tsp)	22.5 mL	900 mg				
40	30 mL; (6 tsp)	30 mL	1200 mg				
50 and above	37.5 mL; (7½ tsp)	37.5 mL	1500 mg				

The safety of re-dosing azithromycin in pediatric patients who yomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, 8 patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.

Pharyngitis/Tonsillitis: The recommended dose of azithromycin for children with pharyngitis/tonsillitis is 12 mg/kg once daily for 5 days. (See chart below.)

PEDIATRIC DOSAGE GUIDELINES FOR PHARYNGITIS/TONSILLITIS (Age 2 years and above, [see Use in Specific Populations (8.4)]) Based on Body Weight

PHARYNGITIS/TONSILLITIS: (5-Day Regimen)								
Dosing Calculated on 12 mg/kg/day for 5 days.								
Weight	Weight 200 mg/5 mL Total mL per Total mg per							
Kg	Day 1 to 5	Treatment Course	Treatment Course					
8	2.5 mL; (½ tsp)	12.5 mL	500 mg					
17	5 mL; (1 tsp)	25 mL	1000 mg					
25	7.5 mL; (1½ tsp)	37.5 mL	1500 mg					
33	10 mL; (2 tsp)	50 mL	2000 mg					
40	12.5 mL; (2½ tsp)	62.5 mL	2500 mg					
Constituting instructions for	or Azithromycin Oral Suspe	ension 600, 900, 1200 m	a bottles. The table below					

indicates the volume of water to be used for constitution:

Amount of water to be added	Total volume after constitution (azithromycin content)	Azithromycin concentration after constitution
9 mL (600 mg)	15 mL (600 mg)	200 mg/5 mL
12 mL (900 mg)	22.5 mL (900 mg)	200 mg/5 mL
15 mL (1200 mg)	30 mL (1200 mg)	200 mg/5 mL

Shake well before each use. Oversized bottle provides shake space. Keep tightly closed. * Effectiveness of the 3-day or 1-day regimen in pediatric patients with community-acquired oneumonia After mixing, store suspension at 5° to 30°C (41° to 86°F) and use within 10 days. Discard after full dosing is completed.

3 DOSAGE FORMS AND STRENGTHS

Azithromycin for oral suspension after constitution contains a flavored suspension. Azithromycin for oral 6.1 Clinical Trials Experience suspension is supplied to provide 200 mg/5 mL suspension in bottles.

4 CONTRAINDICATIONS

4.1 Hypersensitivity

macrolide or ketolide drug

4.2 Hepatic Dysfunction

associated with prior use of azithromycin.

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity

Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Adults Generalized Exanthematous Pustulosis (AGFP). Stevens, Johnson syndrome, and toxic epidermal necrolysis Multiple-dose regimens: Overall, the most common treatment-related adverse reactions in a have been reported in patients on azithromycin therapy. [see Contraindications (4.1)]

Fatalities have been reported. Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) loose stools (4 to 5%), nausea (3%), and abdominal pain (2 to 3%) being the most frequently have also been reported. Despite initially successful symptomatic treatment of the allergic symptoms, No other adverse reactions occurred in patients on the multiple-dose regimens of azithro when symptomatic therapy was discontinued, the alleroic symptoms recurred soon thereafter in some frequency greater than 1%. Adverse reactions that occurred with a frequency of 1% or patients without further azithromycin exposure. These patients required prolonged periods of observation the following: and symptomatic treatment. The relationship of these episodes to the long tissue half-life of azithromycin *Cardiovascular*: Palpitations, chest pain. and subsequent prolonged exposure to antigen is presently unknown

If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that allergic symptoms may reappear when symptomatic therapy has been Nervous System: Dizziness, headache, vertigo, and somnolence discontinued

5.2 Hepatotoxicity

Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been Single 1-gram dose regimen: reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and Overall, the most common adverse reactions in patients receiving a single-dose regime symptoms of hepatitis occur.

5.3 Infantile Hypertrophic Pyloric Stenosis (IHPS)

Following the use of azithromycin in neonates (treatment up to 42 days of life). IHPS has been reported. Adverse reactions that occurred in patients on the single 1-gram dosing regimen of azith Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs.

5.4 QT Prolongation

Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and Single 2-gram dose regimen: torsades de pointes, have been seen with treatment with macrolides, including azithromycin, Cases of Overall, the most common adverse reactions in patients receiving a single 2-gram dose of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients were related to the gastrointestinal system. Adverse reactions that occurred in patients in this receiving azithromycin. Providers should consider the risk of QT prolongation which can be fatal when frequency of 1% or greater included nausea (18%), diarrhea/loose stools (14%), vomiting (79 weighing the risks and benefits of azithromycin for at-risk groups including:

- patients with known prolongation of the QT interval, a history of torsades de pointes, congenital in nature. long QT syndrome, bradvarrhythmias or uncompensated heart failure
- patients on drugs known to prolong the QT interval
- hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (guinidine, patients. procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.

Elderly patients may be more susceptible to drug-associated effects on the QT interval.

5.5 Clostridium difficile-Associated Diarrhea (CDAD)

Clostridium difficile-associated diarrhea has been reported with use of nearly all antibacterial agents. including azithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with The incidence, based on dosing regimen, is described in the table below: antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C, difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

5.6 Exacerbation of Mvasthenia Gravis

Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been loose stools, abdominal pain, vomiting, nausea, and rash. reported in patients receiving azithromycin therapy.

5.7 Use in Sexually Transmitted Infections

Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antibacterial agents used to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis. Appropriate antibacterial therapy and follow-up tests for these diseases should be initiated if infection is confirmed

5.8 Development of Drug-Resistant Bacteria

Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely frequent adverse reactions attributed to treatment were diarrhea, vomiting, abdominal pain, nausea, and to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

6 ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rate the clinical trials of a drug cannot be directly compared to rates in the clinical trials of an may not reflect the rates observed in practice.

In clinical trials, most of the reported side effects were mild to moderate in severity and v Azithromycin is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any upon discontinuation of the drug. Potentially serious adverse reactions of angioedema and jaundice were reported. Approximately 0.7% of the patients (adults and pediatric patients) f multiple-dose clinical trials discontinued azithromycin therapy because of treatment-rel Azithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction reactions. In adults given 500 mg/day for 3 days, the discontinuation rate due to treatment-re reactions was 0.6%. In clinical trials in pediatric patients given 30 mg/kg, either as a single 3 days, discontinuation from the trials due to treatment-related adverse reactions was appro Most of the adverse reactions leading to discontinuation were related to the gastrointestin nausea, vomiting, diarrhea, or abdominal pain. [see Clinical Studies (14.2)]

receiving multiple-dose regimens of azithromycin were related to the gastrointestinal system

- Gastrointestinal: Dyspepsia, flatulence, vomiting, melena, and cholestatic jaundice. Genitourinary: Monilia, vaginitis, and nephritis,
- General: Fatigue.
- Allergic Bash pruritus photosensitivity and angioedema

of azithromycin were related to the gastrointestinal system and were more frequently rep patients receiving the multiple-dose regimen.

a frequency of 1% or greater included diarrhea/loose stools (7%), nausea (5%), abdomin vomiting (2%), dyspepsia (1%), and vaginitis (1%).

pain (7%), vaginitis (2%), dyspepsia (1%), and dizziness (1%). The majority of these complain

Pediatric Patients

Single and Multiple-dose regimens: The types of adverse reactions in pediatric patients were patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or to those seen in adults, with different incidence rates for the dosage regimens recommende

Acute Otitis Media: For the recommended total dosage regimen of 30 mg/kg, the most free reactions (≥1%) attributed to treatment were diarrhea, abdominal pain, vomiting, nausea, a Dosage and Administration (2) and Clinical Studies (14.2)]

Dosage Regimen	Diarrhea %	Abdominal Pain %	Vomiting %	Nausea %
1-day	4.3%	1.4%	4.9%	1.0%
3-day	2.6%	1.7%	2.3%	0.4%
5-day	1.8%	1.2%	1.1%	0.5%

Community-Acquired Pneumonia: For the recommended dosage regimen of 10 mg/kg on Day 1 followed Laboratory data collected from comparative clinical trials employing two 3-day regimens (30 mg/kg or

The incidence is described in the table below:

Dosage Regimen	Regimen stools %		Vomiting %	Nausea 9
5-day	5.8%	1.9%	1.9%	1.9%

Pharyngitis/Tonsillitis: For the recommended dosage regimen of 12 mg/kg on Days 1 to 5, the most headache

tes observed in	Dosage Regimen	Diarrhea %	the table below Abdominal Pain %	Vomiting %	Nausea %	Rash %	Headache %
other drug and	-	5.4%	3.4%	5.6%	1.8%		1.1%
were reversible	5-day	0.4%	3.4%	0.0%	1.070	0.7%	1.170
and cholestatic	With any of the	treatment reg	imens, no other	adverse reacti	ons occurred in j	pediatric pati	ients treated wi
from the 5-day	azithromycin w	ith a frequenc	y greater than 1	%. Adverse re	actions that occu	urred with a	frequency of 1
elated adverse	or less include	d the following					
related adverse	Cardiovascular	: Chest pain.					
le dose or over			constipation, an	orexia, enteriti	s, flatulence, ga	stritis, jaund	ice, loose stool
roximately 1%.	and oral monili						
inal tract, e.g.,			Anemia and leuk				
		m: Headache	(otitis media do	sage), hyperki	nesia, dizziness,	agitation, n	iervousness, ar
	insomnia.						
n adult patients			atigue, fungal in	fection, malais	e, and pain.		
n with diarrhea/	Allergic: Rash a						
tly reported.			is, pleural effusi				
romycin with a				titis, pruritus, s	sweating, urticari	a, and vesicu	ulobullous rash.
r less included	Special Senses						
	6.2 Postmar					<i>c</i>	
					g post-approval		
					of uncertain size		ways possible
					onship to drug ex		and/or nodictr
			lationship may r		ostmarketing pe	nou in aduit	anu/or peulau
			ticaria. and and		neu moluue.		
					a and hypotensic	n Thoro hav	o boon ronorte
nen of 1 gram	QT prolongatio			liai taonyoarui	a anu nypotensio	II. IIICIC IIAV	e been reports
eported than in				noncia flatula	ence, vomiting/d	iarrhoa neo	udomembranou
					ports of tongue of		
thromycin with			a, fatique, malai			10001010101011	
inal pain (5%),			nitis and acute				
inai pain (070);	Hematopoietic:			onal failure al	la vagintio.		
				s cholestatic i	aundice, hepatic	necrosis an	id henatic failur
of azithromycin	[see Warnings			, eneredado j	aunaloo, nopado	110010010, uli	a nopado lanai
his study with a				rtigo, headacl	he, somnolence,	hyperactivi	itv. nervousnes
7%), abdominal	agitation, and s						,
aints were mild			on and anxiety.				
	Skin/Appendag	<i>jes:</i> Pruritus se	rious skin react	ions including	erythema multifo	orme, AGEP, S	Stevens-Johnso
	Syndrome, toxi	c epidermal ne	crolysis, and DF	ESS.			
ere comparable	Special Senses	Hearing distu	rbances includir	g hearing loss	, deafness and/or	r tinnitus, and	d reports of tast
ded in pediatric	smell perversio	on and/or loss.					
	6.3 Laborato	ry Abnormal	ties				
equent adverse	Adults:						
and rash. [see	Clinically signit	ficant abnorma	alities (irrespect	ve of drug re	lationship) occur	ring during	the clinical tria
					han 1%: decrea		
					rum creatine pho		
					mphocytes, neut		
Rash %					lecreased sodiur		
114311 /0					e phosphatase, b		
					had abnormal va	lues at basel	ine. When follov
1.0%			laboratory tests				
0.0%	In multiple-dose clinical trials involving more than 5000 patients, four patients discontinued therap						

In multiple-dose clinical trials involving more than 5000 patients, four patients discontinued therapy because of treatment-related liver enzyme abnormalities and one because of a renal function abnormality.

One, Three, and Five-Day Regimens



by 5 mg/kg on Days 2 to 5, the most frequent adverse reactions attributed to treatment were diarrhea/ 60 mg/kg in divided doses over 3 days), or two 5-day regimens (30 mg/kg or 60 mg/kg in divided doses over 5 days) were similar for regimens of azithromycin and all comparators combined, with most clinically : children under 2 years of age. significant laboratory abnormalities occurring at incidences of 1 to 5%. Laboratory data for patients receiving 30 mg/kg as a single dose were collected in one single center trial. In that trial, an absolute Who should not take azithromycin? neutrophil count between 500 to 1500 cells/mm³ was observed in 10/64 patients receiving 30 mg/kg as a single dose, 9/62 patients receiving 30 mg/kg given over 3 days, and 8/63 comparator patients. No patient had an absolute neutrophil count <500 cells/mm³.

In multiple-dose clinical trials involving approximately 4700 pediatric patients, no patients discontinued therapy because of treatment-related laboratory abnormalities.

DRUG INTERACTIONS 7.1 Nelfinavir

Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased

Patient Information Azithromycin (a-ZITH-roe-MYE-sin) for Oral Suspension

Read this Patient Information leaflet before you start taking azithromycin and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your

What is azithromycin?

Azithromycin is a macrolide antibiotic prescription medicine used in adults 18 years or older to treat certain infections caused by certain germs called bacteria. These bacterial infections include:

- acute worsening of chronic bronchitis
- acute sinus infection
- community-acquired pneumonia
- infected throat or tonsils
- skin infections
- infections of the urethra or cervix
- genital ulcers in men

Azithromycin is also used in children to treat:

- ear infections
- community-acquired pneumonia
- infected throat or tonsils

Azithromycin should not be taken by people who cannot tolerate oral medications because they are very ill or have certain other risk factors including:

- have cystic fibrosis
- have hospital acquired infections
- have known or suspected bacteria in the blood
- need to be in the hospital
- are elderly
- have any medical problems that can lower the ability of the immune system to fight infections

Azithromycin is not for viral infections such as the common cold.

It is not known if azithromycin is safe and effective for genital ulcers in women. It is not known if azithromycin is safe and effective for children with ear infections.

sinus infections, and community-acquired pneumonia under 6 months of age.

It is not known if azithromycin is safe and effective for infected throat or tonsils in

Do not take azithromycin if you:

- have had a severe allergic reaction to certain antibiotics known as macrolides or ketolides including azithromycin and erythromycin.
- have a history of cholestatic jaundice or hepatic dysfunction that happened with the use of azithromycin.

What should I tell my healthcare provider before taking azithromycin? Before you take azithromycin, tell your healthcare provider if you:

- have pneumonia
- have cystic fibrosis
- have known or suspected bacteremia (bacterial infection in the blood)
- have liver or kidney problems
- have an irregular heartbeat, especially a problem called "QT prolongation"
- have a problem that causes muscle weakness (myasthenia gravis)
- have any other medical problems
- are pregnant or plan to become pregnant. It is not known if azithromycin : will harm your unborn baby.
- are breastfeeding or plan to breastfeed. Azithromycin has been reported to pass into breast milk. Talk to your healthcare provider about the best way : to feed your baby while you take azithromycin.

Contact your healthcare provider immediately if you are giving azithromycin to a young child (less than 6 weeks of age) and he or she vomits or becomes irritable when fed.

Tell your healthcare provider about all the medicines you take, including

prescription and non-prescription medicines, vitamins, and herbal supplements. Azithromycin and other medicines may affect each other causing side effects. Azithromycin may affect the way other medicines work, and other medicines may affect how azithromycin works.

Especially tell your healthcare provider if you take:

- nelfinavir
- a blood thinner (warfarin)
- diaoxin
- colchicine
- phenvtoin
- an antacid that contains aluminum or magnesium

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

How should I take azithromycin?

- Take azithromycin exactly as your healthcare provider tells you to take it.
- Azithromycin can be taken with or without food.
- If you take Azithromycin Oral Suspension, shake the bottle well just before you
- Do not skip any doses of azithromycin or stop taking it, even if you begin to feel better, until you finish your prescribed treatment unless you have a serious allergic reaction or your healthcare provider tells you to stop taking azithromycin. See "What are the possible side effects of azithromycin?" If you skip : doses, or do not complete the total course of azithromycin your treatment may not work as well and your infection may be harder to treat. Taking all of your azithromycin doses will help lower the chance that the bacteria will become : resistant to azithromycin
- If the bacteria becomes resistant to azithromycin, azithromycin and other antibiotic medicines may not work for you in the future
- If you take too much azithromycin, call your healthcare provider or get medical : help right away.

What are the possible side effects of azithromycin?

Azithromycin can cause serious side effects, including:

- Serious allergic reactions. Allergic reactions can happen in people taking azithromcyin the active ingredient in Azithromycin Oral Suspension, even after only 1 dose. Stop taking azithromycin and get emergency medical help right away if you have any of the following symptoms of a severe allergic reaction:
- trouble breathing or swallowing
- swelling of the lips, tongue, face
- throat tightness, hoarseness
- rapid heartbeat
- faintness
- skin rash (hives)
- new onset of fever and swollen lymph nodes

Stop taking azithromycin at the first sign of a skin rash and call your healthcare provider. Skin rash may be a sign of a more serious reaction to azithromycin.

 Liver damage (hepatotoxicity). Hepatotoxicity can happen in people who take azithromycin. Call your healthcare provider right away if you have unexplained symptoms such as:

• dark colored urine

- nausea or vomiting loss of appetite
- stomach pain change in the color of your bowel movements
- o fever
- yellowing of your skin or of the whites of your eves weakness
- abdominal pain or
- tenderness
- unusual tiredness

Stop taking azithromycin and tell your healthcare provider right away if you have vellowing of your skin or white part of your eves, or if you have dark urine. These can be signs of a serious reaction to azithromycin (a liver problem)

Serious heart rhythm changes (QT prolongation and torsades de

Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel faint and dizzy. Azithromycin may cause a rare heart problem known as prolongation of the QT interval. This condition can cause an abnormal heartbeat and can be very dangerous. The chances of this happening are higher in people:

- who are elderly
- with a family history of prolonged QT interval
- with low blood potassium
- who take certain medicines to control heart rhythm (antiarrhythmics)
- Worsening of myasthenia gravis (a problem that causes muscle weakness).

Certain antibiotics like azithromycin may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. Call your healthcare provider right away if you have any worsening muscle weakness o breathing problems.

• **Diarrhea.** Tell your healthcare provider right away if you have watery diarrhea. diarrhea that does not go away, or bloody stools. You may experience cramping and a fever. This could happen after you have finished your azithromycin. The most common side effects of azithromycin include:

- nausea
- stomach pain
- vomiting

These are not all the possible side effects of azithromycin. Tell your healthcare provider about any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store azithromycin?

- Store Azithromycin Oral Suspension at 41°F to 86°F (5°C to 30°C).
- Keep Azithromycin Oral Suspension in a tightly closed container.
- Safely throw away any medicine that is out of date or no longer needed

Keep azithromycin and all medicines out of the reach of children. General information about the safe and effective use of azithromycin.

Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use azithromycin for a condition for which it was not prescribed. Do not give azithromycin to other people, even if they have the same symptoms you have. It may harm them.

This Patient Information leaflet summarizes the most important information about azithromycin. If you would like more information, talk with your healthcare provider You can ask your pharmacist or healthcare provider for information about azithromycin that is written for health professionals.

For more information, go to www.taro.com or call 1-866-923-4914.

Active ingredient: azithromycin monohydrate

de vanilla flavor. FD&C red no. 40, hydroxypropyl cellulose, sucrose, tribasic sodium phosphate anhydrous, and xanthan gum.

This Patient Information has been approved by the U.S. Food and Drug Administration

Manufactured by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel, 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532 Issued: June 2020 21264-0620-0 817

azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended 8.4 Pediatric Use

7.2 Warfarin

potentiate the effects of oral anticoagulants such as warfarin, although the prothrombin time was in adults. not affected in the dedicated drug interaction study with azithromycin and warfarin. Prothrombin Pharynoitis/Consilities: Safety and effectiveness in the treatment of pediatric patients with oharynoitis/ 1. followed by one 250 mg tablet on days 2 to 5) or 3 days (500 mg per day for days 1 to 3). Due Seventeen patients (weighing 41,7 kg or less) received a total dose of 60 mg/kg. The following table times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants tonsillitis under 2 years of age have not been established. concomitantly

7.3 Potential Drug-Drug Interactions with Macrolides

Interactions with digoxin, colchicine or phenytoin have not been reported in clinical trials with (458/4949) and 3% of patients (144/4949) were at least 75 years of age. No overall differences azithromycin. No specific drug interaction studies have been performed to evaluate potential drugdrug interaction. However, drug interactions have been observed with other macrolide products. Until reported clinical experience has not identified differences in response between the elderly and younger further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used patients, but greater sensitivity of some older individuals cannot be ruled out. with azithromycin careful monitoring of patients is advised.

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy

Risk Summarv

Available data from published literature and postmarketing experience over several decades with normal doses particularly nausea, diarrhea, and vomiting. In the event of overdosage, general azithromycin use in pregnant women have not identified any drug-associated risks for major birth symptomatic and supportive measures are indicated as required. defects, miscarriage, or adverse maternal or fetal outcomes (see Data). Developmental toxicity studies with azithromycin in rats, mice, and rabbits showed no drug-induced fetal malformations at doses 11 DESCRIPTION administered azithromycin from day 6 of pregnancy through weaning at a dose equivalent to 4 times 135,14P,)-13-[(2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl) oxyl-2-ethyl-3.4.10- by 23% but had no effect on AUC. an adult human daily dose of 500 mg based on body surface area (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown, All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In however, it differs chemically from ervthromycin in that a methyl-substituted nitrogen atom is the U.S. general population, the estimated background risk of major birth defects and miscarriage in incorporated into the lactone ring. Its molecular formula is C., H., N.O., and its molecular weight is clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Human Data

Available data from published observational studies, case series, and case reports over several decades do not suggest an increased risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with azithromycin use in pregnant women. Limitations of these data include the lack of randomization and inability to control for confounders such as underlying maternal disease and maternal use of concomitant medications.

Animal Data Azithromycin administered during the period of organogenesis did not cause fetal malformations in rats and mice at oral doses up to 200 mg/kg/day (moderately maternally toxic). Based on body surface area, this dose is approximately 4 (rats) and 2 (mice) times an adult human daily dose of 500 mg, In rabbits administered azithromycin at oral doses of 10, 20, and 40 mg/kg/day during organogenesis, reduced maternal body weight and food consumption were observed in all groups; no evidence of fetotoxicity or teratogenicity was observed at these doses, the highest of which is estimated to be 2

times an adult human daily dose of 500 mg based on body surface area. In a pre- and postnatal development study, azithromycin was administered orally to pregnant rats from day 6 of pregnancy until weaning at doses of 50 or 200 mg/kg/day. Maternal toxicity (reduced postnatal rat study when up to 200 mg/kg/day of azithromycin was given orally beginning on day 15 constitution, each 5 mL of suspension contains 200 mg of azithromycin. of pregnancy until weaning.

8.2 Lactation Risk Summary

Azithromycin is present in human milk (see Data). Non-serious adverse reactions have been reported Azithromycin is a macrolide antibacterial drug. [see Microbiology (12.4)] in breastfed infants after maternal administration of azithromycin *(see Clinical Considerations)*. There **12.2 Pharmacodynamics** maternal condition.

Clinical Considerations

Advise women to monitor the breastfed infant for diarrhea, vomiting, or rash.

and 48 hours after dosing revealed that azithromycin persisted in breastmilk up to 48 hours.

HO

C H N O •2H O and a molecular weight of 785.0. Azithromycin for oral suspension is supplied in bottles containing azithromycin monohydrate powder unchanged drug, is a major route of elimination. Over the course of a week, approximately 6% of the food consumption and body weight gain; increased stress at parturition) was observed at the higher equivalent to 600 mg, 900 mg, or 1200 mg azithromycin per bottle and the following inactive administered dose appears as unchanged drug in urine. dose. Effects in the offsoring were noted at 200 mg/kg/day during the postnatal development period ingredients: banana flavor, cherry flavor, colloidal silicon dioxide, crème de vanilla flavor, FD&C red no. (decreased viability, delayed developmental landmarks). These effects were not observed in a pre- and 40, hydroxypropyl cellulose, sucrose, tribasic sodium phosphate anhydrous, and xanthan qum. After


12 CLINICAL PHARMACOLOGY 12 1 Mechanism of Action

are no available data on the effects of azithromycin on milk production. The developmental and health Based on animal models of infection, the antibacterial activity of azithromycin appears to correlate with function (GFR >80 mL/min). benefits of breastfeeding should be considered along with the mother's clinical need for azithromycin the ratio of area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) for <u>Patients with Hepatic Impairment</u> and any potential adverse effects on the breastfed infant from azithromycin or from the underlying certain pathogens (*S. pneumoniae* and *S. aureus*). The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical Male and Female Patients trials with azithromycin. Cardiac Electrophysiology

QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy Geriatric Patients Azithromycin breastmilk concentrations were measured in 20 women after receiving a single 2 g oral subjects who received either chloroquine (1000 mg) alone or in combination with oral azithromycin Pharmacokinetic parameters in older volunteers (65 to 85 years old) were similar to those in vound dose of azithromycin during labor. Breastmilk samples collected on days 3 and 6 postpartum as well (500 mg, 1000 mg, and 1500 mg once daily). Co-administration of azithromycin increased the OTc adults (18 to 40 years old) for the 5-day therapeutic regimen. Dosage adjustment does not appear to as 2 and 4 weeks postpartum revealed the presence of azithromycin in breastmilk up to 4 weeks after interval in a dose- and concentration-dependent manner. In comparison to chloroquine alone, the be necessary for older patients with normal renal and hepatic function receiving treatment with this dosing. In another study, a single dose of azithromycin 500 mg was administered intravenously to 8 maximum mean (95% upper confidence bound) increases in QTCF were 5 (10) ms, 7 (12) ms and dosage regimen. [see Geriatric Use (8.5]] women prior to incision for cesarean section. Breastmilk (colostrum) samples obtained between 12 9 (14) ms with the co-administration of 500 mg, 1000 mg and 1500 mg azithromycin, respectively.

8.5 Geriatric Use

10 OVERDOSAG



What are the ingredients in Azithromycin for Oral Suspension?

Inactive ingredients: banana flavor, cherry flavor, colloidal silicon dioxide, crème

12 3 Pharmacokinetic

of azithromycin for the treatment of acute bacterial sinusitis and community-acquired pneumonia in 500 mg tablet.

Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than

younger patients. [see Warnings and Precautions (5.4)]

Adverse reactions experienced at higher than recommended doses were similar to those seen at

trihvdroxy-3.5.6.8.10.12.14-heptamethyl-11-[[3.4.6-trideoxy-3-(dimethylamino)-B-D-xylohexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; 749.00. Azithromycin has the following structural formula:

azithromycin. such as liver enzyme abnormalities and hearing impairment, is varranted. *Isee Adverse* Safety and effectiveness in the treatment of pediatric patients with acute otitis media, acute bacterial volunteers, the mean (SD) pharmacokinetic parameters were AUC. ...=4.3 (1.2) mco-hr/mL; C =0.5 hr. and AUC. ...=3.109 mco-hr/mL for the 5 to 15-vear-old group. sinusitis and community-acquired pneumonia under 6 months of age have not been established. Use (0.2) mcg/mL; T_ = 2.2 (0.9) hours. Two azithromycin 250 mg tablets are bioequivalent to a single

> concentration-time profile of each subject was fit to a 3-compartment model and the ALIC for the In multiple-dose clinical trials of oral azithromycin, 9% of patients were at least 65 years of age fitted concentration profile was comparable between the 5-day and 3-day regimens.

	3-Day Regimen		5-Day Regimen	
Pharmacokinetic Parameter [mean (SD)]	Day 1	Day 3	Day 1	Day 5
C _{max} (serum, mcg/mL)	0.44 (0.22)	0.54 (0.25)	0.43 (0.20)	0.24 (0.06)
Serum AUC ₀ (mcg·hr/mL)	17.4 (6.2)*		14.9	(3.1)*
Serum T _{1/2}	71.8 hr		68.	9 hr

The absolute bioavailability of azithromycin 250 mg capsules is 38%. up to 4, 2, and 2 times, respectively, an adult human daily dose of 500 mg based on body surface Azithromycin for oral suspension contains the active incredient azithromycin. a macrolide antibacterial In a two-way crossover study in which 12 healthy subjects received a single 500 mg dose of area. Decreased viability and delayed development were observed in the offspring of pregnant rats drug, for oral administration. Azithromycin has the chemical name (2R,3S, 4R,5R,8R,10R,11R,12S,

> When azithromycin oral suspension was administered with food to 28 adult healthy male subjects, C increased by 56% and AUC was unchanged.

The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL.

The antibacterial activity of azithromycin is pH related and appears to be reduced with decreasing pH. However, the extensive distribution of drug to tissues may be relevant to clinical activity. Azithromycin has been shown to penetrate into human tissues, including skin, lung, tonsil, and cervix. Extensive tissue distribution was confirmed by examination of additional tissues and fluids (bone, eiaculum, prostate, ovary, uterus, salpinx, stomach, liver, and gallbladder), As there are no data from adequate and well-controlled studies of azithromycin treatment of infections in these additional body sites, the clinical significance of these tissue concentration data is unknown.

Following a regimen of 500 mg on the first day and 250 mg daily for 4 days, very low concentrations were noted in cerebrospinal fluid (less than 0.01 mcg/mL) in the presence of noninflamed meninges. Metaholism

In vitro and in vivo studies to assess the metabolism of azithromycin have not been performed.

Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 ml /min and terminal Azithromycin, as the monohydrate, is a white crystalline powder with a molecular formula of elimination half-life of 68 hr. The prolonged terminal half-life is thought to be due to extensive uptake and subsequent release of drug from tissues. Biliary excretion of azithromycin, predominantly as

Patients with Renal Impairment

Azithromycin pharmacokinetics was investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment. Following the oral administration of a single 1.0 g dose of azithromycin (4 x 250 mg capsules), mean C_m, and AUC, in increased by 5.1% and 4.2%, respectively, in subjects with mild to moderate renal impairment (GFB 10 to 80 ml/min) compared to subjects with normal renal function (GFR >80 mL/min). The mean C____ and AUC_ increased 61% and 35%, respectively, in subjects with severe renal impairment (GFR <10 mL/min) compared to subjects with normal renal

The pharmacokinetics of azithromycin in subjects with hepatic impairment has not been established.

There are no significant differences in the disposition of azithromycin between male and female subjects. No dosage adjustment is recommended based on gender.

In two clinical studies, azithromycin for oral suspension was dosed at 10 mg/kg on day 1, followed by 5 mg/kg on days 2 through 5 in two groups of pediatric patients (aged 1 to 5 years and 5 to 15 years,

respectively). The mean pharmacokinetic parameters on day 5 were $C_{=}=0.216 \text{ mco/ml}$. T = 1.9 hr. hen administered in combination with neffinavir, close monitoring for known adverse reactions of *Isee Clinical Pharmacology (12.3). Indications and Usage (1.2).* Following oral administration of a single 500 mg dose (two 250 mg tablets) to 36 fasted healthy male and AUC, __=1.822 mcg-hr/ml for the 1 to 5-vear-old group and were C__=0.383 mcg/ml. T_=2.4

for 5 days, of whom 31 patients were evaluated for azithromycin pharmacokinetics following a low fat Soontaneous postmarketing reports suggest that concomitant administration of azithromycin may pediatric patients (6 months of age or greater) is supported by adequate and well-controlled trials In a two-way crossover study. 12 adult healthy volunteers (6 males, 6 females) received 1500 mg breakfast. In this study, azithromycin concentrations were determined over a 24 hr period following the of azithromycin administered in single daily doses over either 5 days (two 250 mg tablets on day last daily dose. Patients weighing above 41.7 kg received the maximum adult daily dose of 500 mg. to limited serum samples on day 2 (3-day regimen) and days 2 to 4 (5-day regimen), the serum shows pharmacokinetic data in the subset of pediatric patients who received a total dose of 60 mo/ka.

Pharmacokinetic Parameter [mean (SD)]	5-Day Regimen (12 mg/kg for 5 days)
N	17
C _{max} (mcg/mL)	0.5 (0.4)
T _{max} (hr)	2.2 (0.8)
AUC ₀₋₂₄ (mcg-hr/mL)	3.9 (1.9)

Single dose pharmacokinetics of azithromycin in pediatric patients given doses of 30 mg/kg have not been studied. [see Dosage and Administration (2)] Drug Interaction Studies

rug interaction studies were performed with azithromycin and other drugs likely to be co-administered The effects of co-administration of azithromycin on the pharmacokinetics of other drugs are shown in Table 1 and the effects of other drugs on the pharmacokinetics of azithromycin are shown in Table 2. Co-administration of azithromycin at therapeutic doses had a modest effect on the pharmacokinetics of the drugs listed in Table 1. No dosage adjustment of drugs listed in Table 1 is recommended when co-administered with azithromycin.

Co-administration of azithromycin with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. Nelfinavir significantly increased the C____ and AUC of azithromycin. No dosage adjustment of azithromycin is recommended when administered with drugs listed in Table 2. [see Drug Interactions (7.3)]

1. Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Azithromycin

Co-administered Drug	Dose of Co-administered Drug	Dose of Azithromycin	n	azithrom Co-adminis Pharmacokinet		
				Mean C _{max}	Mean AUC	
Atorvastatin	10 mg/day for 8 days	500 mg/day orally on days 6 to 8	12	0.83 (0.63 to 1.08)	1.01 (0.81 to 1.25)	
Carbamazepine	200 mg/day for 2 days, then 200 mg twice a day for 18 days	500 mg/day orally for days 16 to 18	7	0.97 (0.88 to 1.06)	0.96 (0.88 to 1.06)	
Cetirizine	20 mg/day for 11 days	500 mg orally on day 7, then 250 mg/day on days 8 to 11	14	1.03 (0.93 to 1.14)	1.02 (0.92 to 1.13)	
Didanosine	200 mg orally twice a day for 21 days	1200 mg/day orally on days 8 to 21	6	1.44 (0.85 to 2.43)	1.14 (0.83 to 1.57)	
Efavirenz	400 mg/day for 7 days	600 mg orally on day 7	14	1.04*	0.95*	
Fluconazole	200 mg orally single dose	1200 mg orally single dose	18	1.04 (0.98 to 1.11)	1.01 (0.97 to 1.05)	
Indinavir	800 mg three times a day for 5 days	1200 mg orally on day 5	18	0.96 (0.86 to 1.08)	0.90 (0.81 to 1.00)	
Midazolam	15 mg orally on day 3	500 mg/day orally for 3 days	12	1.27 (0.89 to 1.81)	1.26 (1.01 to 1.56)	

Nelfinavir	750 mg three times a day for 11 days	1,200 mg orally on day 9	14	0.90 (0.81 to 1.01)	0.85 0.78 to 0.93)
Sildenafil	100 mg on days 1 and 4	500 mg/day orally for 3 days	12	1.16 (0.86 to 1.57)	0.92 (0.75 to 1.12)
Theophylline	4 mg/kg IV on days 1, 11, 25	500 mg orally on day 7, 250 mg/day on days 8 to 11	10	1.19 (1.02 to 1.40)	1.02 (0.86 to 1.22)
Theophylline	300 mg orally twice a day for 15 days	500 mg orally on day 6, then 250 mg/day on days 7 to 10	8	1.09 (0.92 to 1.29)	1.08 (0.89 to 1.31)
Triazolam	0.125 mg on day 2	500 mg orally on day 1, then 250 mg/day on day 2	12	1.06*	1.02*
Trimethoprim/ Sulfamethoxazole	160 mg/800 mg/ day orally for 7 days	1200 mg orally on day 7	12	0.85 (0.75 to 0.97)/0.90 (0.78 to 1.03)	0.87 (0.80 to 0.95/0.96 (0.88 to 1.03)
Zidovudine	500 mg/day orally for 21 days	600 mg/day orally for 14 days	5	1.12 (0.42 to 3.02)	0.94 (0.52 to 1.70)
Zidovudine	500 mg/day orally for 21 days	1200 mg/day orally for 14 days	4	1.31 (0.43 to 3.97)	1.30 (0.69 to 2.43)

Table 2. Drug	Interactions: Phari Presence	macokinetic Par of Co-administe			ycin in the
Co-administered Drug	[see Dose of Co-administered Drug	Drug Interactions Dose of Azithromycin	n (7)]	Ratio (with co-admi drug) of Az Pharmacokine (90% Cl); No	nistered ithromycin tic Paramete
				Mean C _{max}	Mean AUC
Efavirenz	400 mg/day for 7 days	600 mg orally on day 7	14	1.22 (1.04 to 1.42)	0.92*
Fluconazole	200 mg orally single dose	1,200 mg orally single dose	18	0.82 (0.66 to 1.02)	1.07 (0.94 to 1.22)
Nelfinavir	750 mg three times a day for 11 days	1,200 mg orally on day 9	14	2.36 (1.77 to 3.15)	2.12 (1.80 to 2.5

- 90% Confidence interval not reported

12.4 Microbiology

Mechanism of Action Azithromycin acts by binding to the 23S rRNA of the 50S ribosomal subunit of susceptible Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of

subunit

mechanism of resistance to azithromycin is modification of the 23S rRNA target, most often shown to be reversible after cessation of azithromycin treatment. Based on the oharmacokinetic data, by methylation. Ribosomal modifications can determine cross resistance to other macrolides, phospholipidosis has been seen in the rat (50 mg/kg/day dose) at the observed maximal plasma lincosamides, and streptogramin B (MLS, phenotype).

Antimicrobial Activity

Azithromycin has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections. [see Indications and Usage (1)]

Gram-Positive Bacteria Staphylococcus aureus Streptococcus agalactiae Streptococcus pneumoniae Streptococcus pvoaenes

Gram-Negative Bacteria Haemophilus ducrevi Haemophilus influenzae Moraxella catarrhalis Neisseria gonorrhoeae

Other Bacteria Chlamvdonhila nneumoniae Chlamvdia trachomatis Mycoplasma pneumoniae

The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for azithromycin against isolates of similar genus or organism group. However, the efficacy of azithromycin in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.

Gram-Positive Bacteria Beta-hemolytic streptococci (Groups C, F, G) Viridans group streptococci

Gram-Negative Bacteria Bordetella pertussis Legionella pneumophila

Anaerobic Bacteria Prevotella bivia Peptostreptococcus species

Other Bacteria Ureaplasma urealyticum

Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

13 NONCLINICAL TOXICOLOGY

Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromvcin has shown no mutagenic potential in standard laboratory tests; mouse lymphoma assay. human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay. In fertility studies conducted in male and female rats, oral administration of azithromycin for 64 to 66 days (males) or 15 days (females) prior to and during cohabitation resulted in decreased pregnancy rate at 20 and 30 mg/kg/day when both males and females were treated with azithromycin. This minimal effect on pregnancy rate (approximately 12% reduction compared to concurrent controls) did not become more the adult daily dose of 500 mg based on body surface area) and it was not observed when only one animal in the mated pair was treated. There were no effects on any other reproductive parameters. and there were no effects on fertility at 10 mg/kg/day. The relevance of these findings to patients being treated with azithromycin at the doses and durations recommended in the prescribing information is 13.2 Animal Toxicology and/or Pharmacology

microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal mice, rats, and dogs given multiple doses of azithromycin. It has been demonstrated in numerous organ systems (e.g., eve, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) in dogs and rats treated with azithromycin at doses which, expressed on the basis of body surface Azithromvcin demonstrates cross resistance with erythromycin. The most frequently encountered area. are similar to or less than the highest recommended adult human dose. This effect has been concentration of 1.3 mcg/mL (1.6 times the observed C_w of 0.821 mcg/mL at the adult dose of 2 g). Similarly, it has been shown in the dog (10 mg/kg/day dose) at the observed maximal serum concentration of 1 mcg/mL (1.2 times the observed C____ of 0.821 mcg/mL at the adult dose of 2 g). Phospholipidosis was also observed in neonatal rats dosed for 18 days at 30 mg/kg/day, which is less than the pediatric dose of 60 mg/kg based on the surface area. It was not observed in neonatal rats treated for 10 days at 40 mg/kg/day with mean maximal serum concentrations of 1.86 mcg/mL, following therapy

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

approximately 1.5 times the C of 1.27 mco/ml at the pediatric dose. Phospholipidosis has been Acute Otitis Media observed in neonatal doos (10 mg/kg/dav) at maximum mean whole blood concentrations of 3.54 Efficacy using azithromycin given over 5 days (10 mg/kg on Day 1 followed by 5 mg/kg on Days 2 to 5). mca/mL, approximately 3 times the pediatric dose C . The significance of these findings for animals Trial 1 and for humans is unknown.

14 CLINICAL STUDIES

14.1 Adult Patients

Acute Bacterial Exacerbations of Chronic Bronchitis

In a randomized, double-blind controlled clinical trial of acute exacerbation of chronic bronchitis rate was 73% for azithromycin and 71% for the control agent. (AECB), azithromycin (500 mg once daily for 3 days) was compared with clarithromycin (500 mg Trial 2 twice daily for 10 days). The primary endpoint of this trial was the clinical cure rate at Days 21 to 24. In a non-comparative clinical and microbiologic trial performed in the United States, where significant For the 304 patients analyzed in the modified intent-to-treat analysis at the Days 21 to 24 visit, the rates of beta-lactamase producing organisms (35%) were found, 131 patients were evaluable for clinical cure rate for 3 days of azithromycin was 85% (125/147) compared to 82% (129/157) for 10 clinical efficacy. The combined clinical success rate (i.e., cure and improvement) at the Day 11 visit days of clarithromycin

The following outcomes were the clinical cure rates at the Days 21 to 24 visit for the bacteriologically success rate was 70% for azithromycin. evaluable patients by pathogen:

Pathogen	Azithromycin (3 Days)	Clarithromycin (10 Days)
S. pneumoniae	29/32 (91%)	21/27 (78%)
H. influenzae	12/14 (86%)	14/16 (88%)
M. catarrhalis	11/12 (92%)	12/15 (80%)

Acute Bacterial Sinusitis

In a randomized, double-blind, double-dummy controlled clinical trial of acute bacterial sinusitis azithromycin (500 mg once daily for 3 days) was compared with amoxicillin/clavulanate (500/125 mg three times a day for 10 days). Clinical response assessments were made at Day 10 and Day 28. The primary endpoint of this trial was prospectively defined as the clinical cure rate at Day 28. For the 594 patients analyzed in the modified intent to treat analysis at the Day 10 visit, the clinical cure rate for 3 days of azithromycin was 88% (268/303) compared to 85% (248/291) for 10 days of amoxicillin/ clavulanate. For the 586 patients analyzed in the modified intent to treat analysis at the Day 28 visit. the clinical cure rate for 3 days of azithromycin was 71.5% (213/298) compared to 71.5% (206/288). with a 97.5% confidence interval of -8.4 to 8.3, for 10 days of amoxicillin/clavulanate.

In an open label, non-comparative study requiring baseline transantral sinus punctures, the following outcomes were the clinical success rates at the Day 7 and Day 28 visits for the modified intent to treat patients administered 500 mg of azithromycin once daily for 3 days with the following pathogens:

Clinical Success Rates of Azithromycin (500 mg per day for 3 Days)

thogen	Day 7	Day 28	
pneumoniae	23/26 (88%)	21/25 (84%)	
influenzae	28/32 (87%)	24/32 (75%)	
catarrhalis	14/15 (93%)	13/15 (87%)	

14.2 Pediatric Patients

From the perspective of evaluating pediatric clinical trials, Days 11 to 14 were considered on-therapy evaluations because of the extended half-life of azithromycin. Days 11 to 14 data are provided for clinical guidance. Days 24 to 32 evaluations were considered the primary test of cure endpoint. Pharvngitis/Tonsillitis

In three double-blind controlled studies, conducted in the United States, azithromycin (12 mg/kg once a day for 5 days) was compared to penicillin V (250 mg three times a day for 10 days) in the treatment pronounced when the dose was increased from 20 to 30 mg/kg/day (approximately 0.4 to 0.6 times of pharyngitis due to documented Group A β-hemolytic streptococci (GABHS or S. progenes). Azithromycin was clinically and microbiologically statistically superior to penicillin at Day 14 and Day 30 with the following clinical success (i.e., cure and improvement) and bacteriologic efficacy rates (for Efficacy using azithromycin given over 3 days (10 mg/kg/day). the combined evaluable patient with documented GABHS):

Three U.S. Streptococcal Pharynoitis Studies Azithromycin vs. Penicillin V EFFICACY RESULTS

	Day 14	Day 30		
Bacteriologic Eradication:				
Azithromycin	323/340 (95%)	255/330 (77%)		
Penicillin V	242/332 (73%)	206/325 (63%)		
Clinical Success (cure plus improvement):				
Azithromycin	336/343 (98%)	310/330 (94%)		
Penicillin V	284/338 (84%)	241/325 (74%)		
Approximately 1% of azithromycin-susceptible S. p	<i>yogenes</i> isolates were i	resistant to azithromy		

In a double-blind, controlled clinical study of acute otitis media performed in the United States. azithromycin (10 mg/kg on Day 1 followed by 5 mg/kg on Days 2 to 5) was compared to amoxicillin/ In a non-comparative clinical and microbiological trial. 248 patients from 6 months to 12 years success rate (i.e., cure plus improvement) at the Day 11 visit was 88% for azithromycin and 88% for (30 mg/kg on Day 1)

was 84% for azithromycin. For the 122 patients who were evaluated at the Day 30 visit, the clinical

Microbiologic determinations were made at the pre-treatment visit. Microbiology was not reassessed at later visits. The following clinical success rates were obtained from the evaluable group:

	Day 11	Day 30
Pathogen	Azithromycin	Azithromycin
S. pneumoniae	61/74 (82%)	40/56 (71%)
H. influenzae	43/54 (80%)	30/47 (64%)
M. catarrhalis	28/35 (80%)	19/26 (73%)
S. pyogenes	11/11 (100%)	7/7 (100%)
Overall	177/217 (82%)	97/137 (73%)

In another controlled comparative clinical and microbiologic study of otitis media performed in [see Dosage and Administration (2)] for constitution instructions with each bottle type. the United States, azithromycin (10 mg/kg on Day 1 followed by 5 mg/kg on Days 2 to 5), was compared to amoxicillin/clavulanate potassium (4:1). This study utilized two of the same investigators as Protocol 2 (above), and these two investigators enrolled 90% of the patients in Protocol 3. For his reason, Protocol 3 was not considered to be an independent study. Significant rates of betalactamase producing organisms (20%) were found. Ninety-two (92) patients were evaluable for clinical and microbiologic efficacy. The combined clinical success rate (i.e., cure and improvement) of those patients with a baseline pathogen at the Day 11 visit was 88% for azithromycin vs. 100% for control: at the Day 30 visit, the clinical success rate was 82% for azithromycin vs. 80% for control.

Microbiologic determinations were made at the pre-treatment visit. Microbiology was not reassessed at later visits. At the Day 11 and Day 30 visits, the following clinical success rates were obtained from the evaluable group:

	Day 11		Day	/ 30
Pathogen	Azithromycin	Control	Azithromycin	Control
S. pneumoniae	25/29 (86%)	26/26 (100%)	22/28 (79%)	18/22 (82%)
H. influenzae	9/11 (82%)	9/9 (100%)	8/10 (80%)	6/8 (75%)
M. catarrhalis	7/7 (100%)	5/5 (100%)	5/5 (100%)	2/3 (66%)
S. pyogenes	2/2 (100%)	5/5 (100%)	2/2 (100%)	4/4 (100%)
Overall	43/49 (88%)	45/45 (100%)	37/45 (82%)	30/37 (81%)

In a double-blind, controlled, randomized clinical study of acute otitis media in pediatric patients from 6 months to 12 years of age, azithromycin (10 mo/kg per day for 3 days) was compared to amoxicillin clavulanate potassium (7:1) in divided doses g12h for 10 days. Each patient received active drug and placebo matched for the comparator.

For the 366 patients who were evaluated for clinical efficacy at the Day 12 visit, the clinical success rate (i.e., cure plus improvement) was 83% for azithromycin and 88% for the control agent. For the Manufactured by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel, 2624761 362 patients who were evaluated at the Days 24 to 28 visit, the clinical success rate was 74% for Dist. by: **Taro Pharmaceuticals U.S.A., Inc.,** Hawthorne, NY 10532 azithromycin and 69% for the control agent. Efficacy using azithromycin 30 mg/kg given as a single dose

A double-blind, controlled, randomized trial was performed at nine clinical centers. Pediatric patients from 6 months to 12 years of age were randomized 1:1 to treatment with either azithromycin (given at 30 mg/kg as a single dose on Day 1) or amoxicillin/clavulanate potassium (7:1), divided g12h for 10 days. Each child received active drug, and placebo matched for the comparator. Clinical response (Cure, Improvement, Failure) was evaluated at End of Therapy (Days 12 to 16) and Test of Cure (Days 28 to 32). Safety was evaluated throughout the trial for all treated subjects.

For the 321 subjects who were evaluated at End of Treatment, the clinical success rate (cure plus

improvement) was 87% for azithromycin, and 88% for the comparator. For the 305 subjects who were evaluated at Test of Cure, the clinical success rate was 75% for both azithromycin and the comparator,

clavulanate potassium (4:1). For the 553 patients who were evaluated for clinical efficacy, the clinical of age with documented acute otitis media were dosed with a single oral dose of azithromycin

the control agent. For the 521 patients who were evaluated at the Day 30 visit, the clinical success clinical success rate (i.e., cure plus improvement) at Day 10 was 89% and for the 242 patients evaluable at Days 24 to 28, the clinical success rate (cure) was 85%.

Presumed Bacteriologic Eradication					
Day 10 Days 24 to 28					
70/76 (92%)	67/76 (88%)				
30/42 (71%)	28/44 (64%)				
10/10 (100%)	10/10 (100%)				
110/128 (86%)	105/130 (81%)				
	Day 10 70/76 (92%) 30/42 (71%) 10/10 (100%)				

16 HOW SUPPLIED/STORAGE AND HANDLING

Azithromycin for Oral Suspension, USP after constitution contains a flavored suspension. Azithromycin for Oral Suspension, USP is supplied to provide 200 mg/5 mL suspension in bottles as follows:

Azithromycin contents per bottle	NDC
600 mg	51672-4200-5
900 mg	51672-4200-7
1200 mg	51672-4200-3

Storage: Store dry powder below 30°C (86°F). Store constituted suspension between 5° to 30°C (41°). to 86°F) and discard when full dosing is completed.

7 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

General Patient Counseling

Azithromycin oral suspension can be taken with or without food.

Patients should also be cautioned not to take aluminum- and magnesium-containing antacids and romycin simultaneously

The patient should be directed to discontinue azithromycin immediately and contact a physician if any signs of an allergic reaction occur

Direct parents or caregivers to contact their physician if vomiting and irritability with feeding occurs in the infant

Patients should be counseled that antibacterial drugs including azithromycin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When azithromycin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of the therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by azithromycin or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible.

This product's label may have been updated. For current full prescribing information, please visit

Issued: June 2020 21264-0620-0 817